BioStem Technologies, Inc. · NASDAQ:BSEM
BioStem Technologies — Planet Microcap Conference Las Vegas 2026
17 slides from BioStem Technologies's conference presentation, Jun 17, 2026
Slide 1: Company Presentation
Company Presentation Planet Microcap Conference Las Vegas – June 17, 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, certain statements, estimates and projections provided by BioStem Technologies,
Slide 3: Our Mission
To create and deliver the most Our advanced wound healing technologies in the world Mission In Relentless Pursuit of Healing
Slide 4: BioStem Snap Shot
BioStem Snap Shot Corporate Profile Ticker: BSEM Headquarters: Pompano Beach, FL Share Price: $4.15 Market Cap: $72 million Shares Outstanding: 16.9 million, ~20 million (Fully Diluted) Recent 1Q26 Revenue: $6.1 million Financials 1Q26 Gross Margin: 61% 1Q26 Cash and Cash Equivalents: $13.7 million
Slide 5: Key Corporate Developments
Key Corporate Developments BioTissue Acquisition • Closed acquisition of BioTissue surgical and wound care business and progressed integration initiatives including reassignment of all GPO contracts, and expansion of direct sales force Progression on Pathway to Uplisting • Completion and publication
Slide 6: The Need for Perinatal Allografts vs SOC
The Need for Perinatal Allografts vs SOC Regenerative medicine promotes faster healing and reduces complications* Faster Healing Patient Impact1 Perinatal allografts optimize the healing environment, accelerating tissue regeneration • ~155,000 lower limb amputations annually Minimize Scarring & Adhe
Slide 7: Large and Underserved ~$23B US Soft Tissue Allograft Opportunity
Large and Underserved ~$23B US Soft Tissue Allograft Opportunity Driving adoption of perinatal tissue allografts for multiple market segments 1 Orthopedics/Sports Medicine 4 Urology/ Colorectal US TAM: ~$2.3B US TAM: ~$1.5B Knee Osteoarthritis | Soft Tissue Radical Prostatectomy | Urethral / Repair|
Slide 8: BioStem Snapshot
BioStem Snapshot Well positioned for market expansion and growth Differentiated Technology Strong Foundation 3 Industry-Leading Technologies Experienced National Sales Force BioRetain®, CryoTek® and SteriTek® all demonstrate superiority > 25 direct reps and >30 independent agents plus GPO contracts
Slide 9: Our Regenerative Medicine Solutions
Our Regenerative Medicine Solutions A complete portfolio of perinatal tissue allografts Orthopedics/Sports Medicine · Foot & Ankle · Urology / Colorectal · Chronic Wound Care NON-WOUND / SURGICAL WOUND Spine · Women's Health Clarix 1K Clarix 100 Clarix Flo Neox 1K Neox 100 Neox RT Cryopreserved amni
Slide 10: Expanded Payor Mix Towards Commercial Reimbursement
Expanded Payor Mix Towards Commercial Reimbursement BioTissue acquisition opens up the larger Hospital market with favorable coverage and economics Physician Office Hospital Market Market Vendaje Neox, Clarix BioTissue Acquisition CMS Payor Commercial Payors 10
Slide 11: Multiple Commercial Growth Levers
Multiple Commercial Growth Levers EXPAND DIRECT SALES TEAM TO 40+ BY YEAR-END DRIVE ADOPTION WITH PEER-to-PEER SELLING INCREASE PAYOR COVERAGE AND PATIENT ACCESS EXECUTING PRODUCT ROAD MAP Primary revenue generating states Opportunities for growth 11
Slide 12: Results of DFU and Ambulate Studies
Results of DFU and Ambulate Studies Multiple robust randomized control trials demonstrate clinical efficacy Superior Outcomes with BioRetain® Ambulate Study2 Allograft in Diabetic Foot Ulcers1 • Trial designed to meet the most rigorous • Trial design to treat the most severe patient selection and cl
Slide 13: World-Class Manufacturing
World-Class Manufacturing AATB® accredited, cGTP facility State of the art, vertically integrated manufacturing facility Currently processing 30k sq cm monthly Capacity up to 100K sq cm monthly to support future growth 6,100 sq ft dedicated area; 3,000 sq ft ISO clean room space Located in Pompano B
Slide 14: Management Team
Management Team Accomplished team with deep industry experience Katherine Gorrell Jason Matuszewski LSSBB Andrew Van Vurst CTBS Brandon Poe Michael Fortunato CPA Barry Hassett Chief Legal and Compliance Chief Executive Officer Chief Operating Officer Chief Financial Officer Chief Accounting Officer
Slide 15: Financial/Capital Markets Outlook
Financial/Capital Markets Outlook Strong Financial Investing for growth in our surgical revenue base; Acquired assets generated $29M in 2025 and largely unaffected by CMS price changes Profile Transition period for wound business in 1H 2026 as market digests CMS payment changes Efficient manufacturi
Slide 16: 2026 Catalyst Roadmap
2026 Catalyst Roadmap Building momentum through integration, expansion, and value creation Successful integration Uplist to Nasdaq Sales expansion • Maintain acquired team, • Complete the financial audit • Expand direct Sales team to customer and revenue with KPMG 40+ by year-end • Reassign GPO agre
Slide 17: Thank you
Thank you June 2026 BSEM
BioStem Technologies — Planet Microcap Conference Las Vegas 2026 on 6ix